Annual report pursuant to Section 13 and 15(d)

Acquisition of Ohr Pharmaceutical, Inc. (Tables)

v3.20.4
Acquisition of Ohr Pharmaceutical, Inc. (Tables)
 12 Months Ended
Sep. 30, 2020
Acquisition of Ohr Pharmaceutical, Inc.  
Schedule of Consideration Acquired

 

 

 

 

Number of shares of the combined company to be owned by Ohr security holders

    

 

2,829,248

Fair value per share of Ohr common stock as of July 11, 2019

 

$

4.14

Fair value of Ohr shares outstanding

 

 

11,713,087

Fair value of options assumed

 

 

63,840

Fair value of common stock and options issued

 

 

11,776,927

 

 

 

 

Transaction costs

 

 

884,981

Total cost of the Ohr acquisition

 

$

12,661,908

 

Schedule of Business Acquisitions, by Acquisition

 

 

 

 

Cash and cash equivalents

    

$

752,419

Prepaid expenses and other current assets

 

 

115,769

Investment in DepYmed

 

 

586,418

Intangible assets

 

 

250,000

Warrant liability

 

 

(470,093)

Accounts payable and accrued expenses

 

 

(493,055)

Fair value of net assets acquired

 

 

741,458

Research and development expense- License acquired

 

 

11,920,450

Total cost of Ohr Acquisition

 

$

12,661,908